Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Pancreatic cancer

Unlocking the promise of RAS inhibition in pancreatic cancer

The advent of next-generation RAS inhibitors brings renewed optimism to the care of patients with pancreatic cancer after decades of failure for novel therapeutics. A recent study highlights the potent antitumour activity of the multi-selective RAS(ON) inhibitor RMC-7977 across a spectrum of preclinical pancreatic cancer models.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Mutant KRAS drives oncogenesis in PDAC via cell-intrinsic and cell-extrinsic mechanisms.


  1. Buscail, L., Bournet, B. & Cordelier, P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 17, 153–168 (2020).

    Article  CAS  PubMed  Google Scholar 

  2. Kemp, S. B. et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 13, 298–311 (2023).

    Article  CAS  PubMed  Google Scholar 

  3. Kim, D. et al. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature 619, 160–166 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Jiang, J. et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 14, 994–1017 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Arbour, K. C. et al. 652O preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) [abstract]. Ann. Oncol. 34, S458 (2023).

    Article  Google Scholar 

  6. Wasko, U. N. et al. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature 629, 927–936 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Holderfield, M. et al. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature 629, 919–926 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mahadevan, K. K. et al. KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8 + T cells. Cancer Cell 41, 1606–1620.e8 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531–542 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Haldar, S. D. et al. Abstract CT036: safety and immunogenicity of a first-in-human mutant KRAS long peptide vaccine combined with ipilimumab/nivolumab in resected pancreatic cancer: preliminary analysis from a phase I study. Cancer Res. 83 (Suppl. 8), CT036–CT036 (2023).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Nilofer S. Azad.

Ethics declarations

Competing interests

N.S.A. reports clinical research funding and consultant/advisory fees from Revolution Medicines, Mirati Therapeutics and Bristol Myers Squibb. S.D.H. declares no competing interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haldar, S.D., Azad, N.S. Unlocking the promise of RAS inhibition in pancreatic cancer. Nat Rev Gastroenterol Hepatol (2024).

Download citation

  • Published:

  • DOI:


Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer